Mechanism of 2-methoxyestradiol-induced apoptosis in myelodysplastic syndrome MUTZ-1 cell line.
- Author:
Guo-Hua XIA
1
;
Bao-An CHEN
;
Ze-Ye SHAO
;
Hui-Xia LU
;
Döhner KONSTANZE
;
Döhner HARTMUT
Author Information
1. Department of Hematology, The Affiliated Zhongda Hospital, Clinical Medical College of Southeast University, Nanjing 210009, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Apoptosis;
drug effects;
Cell Cycle;
drug effects;
Cell Line, Tumor;
Cell Proliferation;
drug effects;
Dose-Response Relationship, Drug;
Estradiol;
analogs & derivatives;
pharmacology;
Humans;
L-Lactate Dehydrogenase;
metabolism;
Myelodysplastic Syndromes;
pathology
- From:
Journal of Experimental Hematology
2007;15(2):296-301
- CountryChina
- Language:English
-
Abstract:
The study was aimed to investigate the mechanism of proliferation inhibition and apoptosis of MDS-RAEB MUTZ-1 cells induced by 2-methoxyestradiol (2-ME), the cell proliferation was determined by MTT assay, apoptosis rate was determined with annexinV-FITC/PI double staining and cell cycle was analyzed by flow cytometry (FCM) after MUTZ-1 cells were treated with different concentrations of 2-ME; the changes of morphologic features of MUTZ-1 cells were observed with Wright-Giemsa's staining; lactate dehydrogenase was determined by Beckman Counter; and agarose gel electrophoresis was used to verify whether 2-ME can induce apoptosis of MUTZ-1 cells. The results showed that 2-ME inhibited the proliferation of MUTZ-1 cells in a dose-and time-dependent manner and caused a sustained arrest at G(2)/M phase in MUTZ-1 cells; the typical apoptotic morphological features appeared in MUTZ-1 cells; the production of lactate dehydrogenase was up-regulated and the marked DNA ladder pattern of internucleosomal fragmentation was observed. It is concluded that the mechanism of proliferation inhibition and apoptosis of MUTZ-1 cells induced by 2-ME is probably related with the G(2)/M cell cycle arrest; 2-ME may be a potentially adjunctive anticancer drug useful to treat myelodysplastic syndrome.
